Approximately 50% of all cutaneous melanomas harbor activating BRAF V600 mutations; among, these 10-30% carry the V600K mutation. Clinically, patients with V600K tumors experience distant metastases sooner and have an increased risk of relapse and shorter survival than patients with V600E tumors. Despite the clinical and other histopathological differences between these BRAF tumor subtypes, little is known about them at the genomic level. Herein, we systematically compared BRAF V600E and V600K skin cutaneous melanoma (SKCM) samples from the Cancer Genome Atlas (TCGA) for differential protein, gene, and microRNA expression genome-wide using the Mann-Whitney U-test. Our analyses showed that elements of energy-metabolism and protein-translation pathways were upregulated and that proapoptotic pathways were downregulated in V600K tumors compared with V600E tumors. We found that c-Kit protein and KIT gene expressions were significantly higher in V600K tumors than in V600E tumors, concurrent with significant downregulation of several KIT-targeting microRNAs (mir) including mir-222 in V600K tumors, suggesting KIT and mir-222 might be key genomic contributors toward the clinical differences observed. The relationship that we uncovered among KIT/c-Kit expression, mir-222 expression, and growth and prosurvival signals in V600 tumors is intriguing. We believe that the observed clinical aggressiveness of V600K tumors compared to V600E tumors may be attributable to the increased energy metabolism, protein translation and prosurvival signals compared with V600E tumors. If confirmed using larger numbers of V600K tumors, our results may prove useful for designing clinical management and targeted chemotherapeutical interventions for BRAF V600K-positive melanomas. Finally, the small sample size in V600K tumors is a major limitation of our study. Melanoma Res 27:527-535
Introduction
BRAF is a serine/threonine protein kinase that activates the mitogen-activated protein kinase/ERK-signaling pathway [1] . Approximately 40-60% of cutaneous melanomas harbor activating BRAF mutations [2] . The majority of the BRAF mutations constitute a substitution of the valine residue at position 600 by a glutamate (V600E) through mutation of a single nucleotide GTG to GAG. Another prevalent BRAF mutation at the same residue is V600K mutation in which the valine residue is replaced by a lysine through two nucleotide substitutions (GTG to AAG). The V600K mutation occurs in 10-30% of all BRAF V600 melanomas [2] [3] [4] [5] [6] . Other less common BRAF mutations at the V600 residue include V600R and V600D [1] .
Patients with V600K and those with the V600E mutation seem to have some distinctive clinical features. Patients with V600K tumors appear to be older (over 50) men, and the tumors often occur in the head and neck area (prone to sun damage) [4, [7] [8] [9] [10] [11] [12] [13] . Pathologically, V600K tumors appear to be thicker and are more mitotically active than V600E tumors [8] . Clinically, patients with V600K tumors have an increased risk for brain and lung metastases and are at a siginficantly increased risk of relapse and have a shorter time from diagnosis to metastasis than those with V600E tumors [4, [8] [9] [10] [11] 13] . Despite these differences, a large clinical trial showed that V600K tumors were sensitive to vemurafenib, a BRAF inhibitor, and that patients with V600K or V600E tumors, when treated with vemurafenib, had similar overall survival and progression-free survival outcomes [10] .
Although the clinical and histopathological differences between V600K and V600E tumors are well documented, little is known about their genomic differences. In this study, we systematically compared protein expression, RNA-seq gene expression, and miRNA-seq microRNA expression between BRAF V600K and BRAF V600E melanoma tumor samples from TCGA. In addition, we analyzed somatic mutation, copy number alteration, and clinical data between those two BRAF tumor subtypes. We aimed to identify the Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.melanoma.com.
signaling pathway that might contribute toward the clinical and histopathological differences observed between the two subtypes of BRAF melanoma. Our analysis indicated an intriguing relationship among KIT gene expression and c-Kit protein expression, mir-222 expression, and growth and prosurvival signals in V600 tumors. Although the number of V600K tumor samples available for our analyses was small, our results may provide useful clues for clinical management and targeted chemotherapeutical interventions for the two BRAF melanoma subtypes.
Patients and methods
We used the online DAVID Bioinformatics Resources 6.7 [14] for gene ontology (GO) analysis. We carried out all differential expression analyses (protein, gene, and microRNA) between V600E and V600K tumors in Matlab using the Mann-Whitney U-test (two-sided) [15] . For our survival analysis, we fit the multivariate Cox proportional hazards model using SAS software (SAS Institute Inc., Cary, North Carolina, USA).
Data
We downloaded all genomic data from the TCGA data portal (https://tcga-data.nci.nih.gov/tcga/). We downloaded additional information on the four melanoma subtypes: BRAF, NF1, RAS, and triple wild type from the TCGA cutaneous melanoma publication [2] . Information on the subtypes included clinical, mutation, copy number variation, and other related characteristics. For RNA-seq data, we log 2 -transformed the normalized read counts (rsem.genes.normalized_results) using [log 2 (count + 1)] but carried out no further normalization. For the reverse phase protein array (RPPA) protein expression data, we used normalized data from TCGA without further normalization or transformation; negative values were found from the normalization by TCGA (http:// bioinformatics.mdanderson.org/main/TCPA:Overview).
TCGA provided RNA-seq data on ∼ 24 000 genes for 124 BRAF V600E tumor samples and 17 V600K tumor samples. TCGA sequenced 1046 micro-RNAs in 121 V600E and 17 V600K tumor samples. TCGA profiled protein expression in up to 91 BRAF V600E tumors and 17 BRAF V600K tumors. Not all proteins were analyzed in all samples; among the 276 proteins or protein modifications TCGA studied, only 103 were analyzed in four or more V600K tumor samples.
Survival
As described in the TCGA publication [2] , an accurate stage of disease at the time of the TCGA biospecimen procurement was often unavailable. The available pathology data such as primary tumor staging information were dated to the patient's initial melanoma diagnosis, not to the time of tumor procurement (i.e. entry into the TCGA database). Often, there was a time-lag (mean: 1272.9 days; median: 432 days for BRAF-mutation patients) between the initial melanoma diagnosis and TCGA biospecimen procurement. TCGA's analysis of melanoma survival [2] used the patient's survival from the time of TCGA biospecimen procurement until death or loss to follow-up. Our analysis of melanoma survival used the patient's survival from diagnosis until death or loss to follow-up. Our survival analysis allowed for right censoring to account for loss to follow-up and left truncation to account for the feature that patients could only enter the study if they survived from diagnosis until TCGA specimen procurement. Of the 124 patients with V600E tumors and 17 patients with V600K tumors, TCGA had matched clinical data on 106 and 13, respectively. Among these 119 patients with clinical records, 48 were dead and 71 remained alive at last contact (i.e. were censored for survival analysis).
Results and discussion

Survival comparison between BRAF subtypes
An apparent trend toward shorter overall survival for patients with V600K tumors than for those with V600E tumors (Fig. 1) was not statistically significant [hazard ratio = 1.4, 95% confidence interval (0.62, 3.25), P = 0.39], similar to other published findings. Nonetheless, this tendency toward shorter survival in V600K patients is consistent with the literature findings that V600K tumors tend to have less favorable outcomes than V600E tumors [4, [8] [9] [10] [11] 13] .
Overall gene, microRNA, and protein expression comparisons between BRAF subtypes Among the~24 000 genes with RNA-seq gene expression levels from TCGA, we found 1675 differentially expressed with P value less than 0.05 between BRAF subtypes; among these, 593 were upregulated and 1082 were downregulated in BRAF V600K tumors compared with V600E tumors.
GO analysis applied to the top 250 (as ordered by P values for differential expression) genes upregulated in V600K tumors compared with V600E tumors showed that the upregulated genes were over-represented in metabolic processes (Table 1) , consistent with upregulation of proliferation signals in those tumors from protein expression analysis. Among the top 250 genes downregulated in V600K tumors compared with V600E tumors, GO analysis showed an over-representation in embryonic development pathways (Table 1) .
Among the 103 proteins for which data were available for at least four V600K tumor samples, 14 were differentially expressed with P value less than 0.05 between BRAF subtypes; among these, seven were upregulated and seven were downregulated in BRAF V600K tumors compared with V600E tumors (Table 2 and Supplementary Figs S1A and S1B, Supplemental digital content 1, http:// links.lww.com/MR/A6).
Among the significantly downregulated proteins in V600K tumors were Bak and caspase-7 ( Fig. 2) . Bak belongs to the BCL-2 protein family and acts as antiapoptotic or proapoptotic regulator. Caspase-7 is a member of the cysteine-aspartic acid protease (caspase) family that plays a central role in the execution phase of cell apoptosis. Another member of the proapoptotic family of proteins, Bid, was also downregulated in V600K samples (Table 2) . Bid is also a member of the BCL-2 family of cell death regulators. Taken together, these results suggest that the proapoptotic signaling pathways might be downregulated to promote cell survival and growth in V600K tumors.
Among the proteins upregulated in V600K tumors compared with V600E tumors, S6 (RPS6), and eEF2 are involved in mRNA translation and ribosomal biogenesis. S6 is a downstream target of the mTOR/S6K signaling pathway involved in growth factors and mitogen-induced protein translation [16] [17] [18] . eEF2 is an essential factor for protein synthesis. Besides eEF2, eEF2K, and phosphorylated 4E-BP1 (4E-BP1_pT37_T46) were upregulated in V600K tumors compared with V600E tumors, although these changes in protein levels were not statistically significant (data not shown). eEF2K is a conserved protein kinase in the calmodulin-mediated signaling pathway that links activation of cell surface receptors to cell division and is involved in the regulation of protein synthesis. It phosphorylates eukaryotic elongation factor 2 and thus inhibits the eukaryotic elongation factor 2 function. eEF2K is expressed at high levels in certain cancers, where it may act to aid cell survival, e.g. during nutrient starvation [19] . AMPactivated protein kinase is an upstream signaling molecule of the mTOR pathway providing a link between energy and mTOR pathways [16] [17] [18] . Tuberin (TSC2), also upregulated in V600K tumors compared with V600E tumors (Fig. 2) , Fitted survival probabilities as function of days after diagnosis based on Cox regression model for two skin cutaneous melanoma subtypes: BRAF V600K and V600E. Circles indicate censored patients. The plots are based on 13 subjects with V600K tumors and 106 with V600E tumors. The apparent difference between survival curves was not statistically significant (P = 0.39). forms a complex with TSC1, and the complex serves to control various cellular functions as an important upstream hub for the mTOR pathway [16] [17] [18] . These results suggest that the mTOR pathway may be differentially affected between V600K and V600E tumors. Finally, the phosphorylated mTOR protein (mTOR_pS2448) level was also elevated in V600K BRAF tumors compared with V600E BRAF tumors, although the elevation did not reach statistical significance (Fig. 3) . The other proteins that were upregulated in V600K tumors compared with V600E tumors include TFRC and PCNA. TFRC is a cell surface receptor necessary for cellular iron uptake by the process of receptormediated endocytosis. PCNA is involved in DNA replication. It is not clear why these two proteins were upregulated in V600K tumors compared with V600E tumors. Finally, c-Kit, a receptor tyrosine kinase that plays a multifunctional role in melanogenesis, cell growth, migration, and survival [20, 21] , was also upregulated in V600K tumors.
Among the 1046 microRNAs analyzed by TCGA, 106 were differentially expressed with P value less than 0.05 between V600E and V600K SKCM tumors; among these, 29 were upregulated and 77 were downregulated in V600K tumors compared with V600E tumors. Interestingly, several 
The negative values were resulted from normalization by TCGA (http://www.mdanderson.org/ ). No further normalization/standardization was carried out for data shown here.
Fig. 2
Boxplots of expression levels of selected differentially expressed proteins between V600K and V600E tumors. The protein expression data were taken from TCGA reverse phase protein array analysis without further standardization and transformation. AMPK, AMP-activated protein kinase.
of the most significantly downregulated microRNAs (Table 3) were found in V600K tumors compared with V600E tumors. Several of them, such as mir-222 [22] (Fig. 4) , mir-34b/c [23] , mir-19b-2 [24] , and mir-148a, are either known or predicted to target the KIT gene (see below) ( Supplementary Fig. S2 , Supplemental digital content 2, http://links.lww.com/MR/A7). Upregulated miRNAs in V600K tumors compared with V600E tumors include mir-330 and let7g, both of which appear to have antiproliferative effects [25] .
Preliminary synthesis of gene, protein, and microRNA expression findings
Our gene expression analysis suggested the upregulation of metabolic processes and downregulation of embryonic development pathways in V600K tumors compared with V600E tumors. Our protein expression analysis suggested that proapoptotic pathways were downregulated, possibly contributing toward enhanced cell survival and growth in V600K tumors compared with V600E tumors. In addition, our protein expression analysis indicated that the mTOR signaling pathway may be differentially affected between the two BRAF subtypes. Our analyses to this point, however, failed to uncover a single regulatory or signaling feature that might underpin or connect these differentially expressed pathways.
Perhaps the most striking feature to emerge from our differential expression analyses was the fact that c-Kit was significantly upregulated in V600K tumors whereas several micro-RNAs known or predicted to target KIT were significantly downregulated. Both KIT gene expression and protein expression were upregulated in V600K tumors compared with V600E tumors (P = 0.03) (Fig. 5 ). In addition, using 352 matched SKCM protein expression (RPPA) and gene expression (RNA-seq) samples, we found a strong correlation in the expression levels between c-Kit and KIT (Spearman's ρ = 0.86, P < 0.001). The coordinated upregulation of c-Kit protein level and KIT gene expression and concomitantly downregulation of several KIT-targeting microRNAs suggested to us that the c-Kit signaling pathway is possibly an important feature distinguishing between V600E and V600K BRAF tumors. These observations led us to focus our downstream analysis on KIT/c-Kit and its signaling pathways.
Additional findings related to mir-222 and the c-Kit signaling pathway
In the TCGA data, mir-222 expression was correlated negatively with that of KIT in all 450 SKCM samples (Spearman's ρ = − 0.27, P = 7.0E-09) and 14 V600K samples (Spearman's ρ = − 0.32, P = 0.26) (Fig. 6) . Upregulation of mir-222 results in marked loss of KIT transcript and c-Kit protein by targeting the 3′-untranslated region of KIT in papillary thyroid carcinoma [26] , Boxplots of expression levels of mTOR_pS2448-R-C protein between V600K and V600E tumors. The protein expression data were taken from TCGA reverse phase protein array analysis without further standardization and transformation. Boxplots of mir-222 expression levels across two skin cutaneous melanoma BRAF tumor subtypes defined by TCGA melanoma working group. The numbers of microRNA-seq samples for V600K and V600E subtypes were 17 and 121, respectively.
gastrointestinal stromal tumors [27, 28] , erythroleukemic cells [29] , prostate cancer [30] , acute myelogenous leukemia [31] , cutaneous melanoma [32] , and human umbilical vein endothelial cells [33] .
Besides targeting KIT, mir-222 has been shown to regulate the expression of other genes including BIM [34] , DDIT4 [35] , ETV1 [28] , ICAM1 [36] , MMP1 and SOD2 [37] , p27 (KIP1) and p57 (KIP2) [22, 38, 39] , PTEN and TIMP3 [40] , PUMA [41] , and TRPS1 [42] . The role of mir-221/222 in cancer has been reviewed in Garofalo et al. [43] .
To examine whether downregulation of mir-222 is associated with upregulation of metabolism in other TCGA tumor types, we mapped all TCGA RNASeqV2 samples to all miRNA-seq samples (from HiSeq only). In total, 8343 samples from 31 unique tumor types were matched between the two platforms (Supplementary Table S1 , Supplemental digital content 3, http://links.lww.com/MR/A8). The number of matched samples in each tumor type ranged from 57 to 1224. We then computed the pairwise Spearman's rank correlation between mir-222 and each of the 20 531 genes for each of the 31 tumor types. This resulted in 31 pairwise correlation coefficients between each gene and mir-222, one for each tumor type. Not surprisingly, GO terms related to metabolism are enriched with the 150 most negatively correlated genes, whereas GO terms related to immune response and cell motility are enriched with the 150 most positively correlated genes (data not shown). KIT was among the top 150 most positively correlated genes. When we considered only SKCM tumors, the enrichment of metabolism genes among the 150 most negatively correlated Boxplots of c-Kit protein (top) and KIT gene (bottom) expression across the two skin cutaneous melanoma mutation subtypes (BRAF V600E and V600K) defined by TCGA melanoma working group. The numbers samples for V600K and V600E, respectively, were 13 and 91 for reverse phase protein array; and 17 and 124 for RNA-seq. Both RNAseq and reverse phase protein array (protein expression) data were normalized by TCGA; we subsequently applied a log 2 -transformation to the RNA-seq data before analysis. Scatter plots of KIT and mir-222 expression in all skin cutaneous melanoma tumors (top) and BRAF V600K only skin cutaneous melanoma tumors (bottom). The red lines are the least-squares fits. In this Figure, we first identified matching RNA-seq and miRNA-seq samples and extracted KIT expression and mir-222 expression respectively.
genes persisted. These results suggest a link between downregulation of mir-222 and the over-representation of metabolism genes among genes whose expression is upregulated in V600K tumors, although the exact relationship between the two is unclear.
TCGA had previously identified 18 significantly mutated genes in melanoma; [2] three (GNA11, KIT, and PTEN) showed proportionally higher numbers of mutations in V600K tumors than in V600E tumors (Table 4) . A closer examination of the mutations in each of the three genes did not find a pattern of association between the mutations and c-Kit expression among the 13 V600K tumors (Table 5 ). In fact, the three V600K tumors with the highest c-Kit expression were all wild type for the three genes (highlighted in Table 5 ). We observed no evident association between the elevated expression of c-Kit and any copy number changes in the KIT gene (Table 5) . No differential methylation in KIT promoter was found between V600K and V600E tumors (data not shown).
In conclusion, our analyses of multiple genomic data suggest that both c-Kit protein and KIT gene expression levels were significantly higher in V600K tumors than in V600E tumors. Concurrently, mir-222 expression was significantly downregulated in V600K tumors compared with V600E tumors. We also found that these differential changes concomitantly correlated with increased proliferation and prosurvival signals/pathways in V600K tumors compared with V600E tumors, providing a plausible link between the observed clinical phenotypes and genomics between the two subtype BRAF tumors.
Discussion
An increasing number of studies have shown that BRAF V600K and V600E tumors are not identical. V600K tumors are more aggressive in that patients with these tumors have a significantly higher risk for relapse and a shorter time from diagnosis to metastasis compared with those with V600E tumors. Despite the clinical and histopathological differences, little is known about the underlying mechanisms at the genomic level.
Structurally, both V600E and V600K mutations are located in the activation segment helix 1 inside the kinase domain and are predicted to perturb the structure of the helix, thus promoting dimerization of the protein [44] . The exact structural basis for the clinical and histopathological differences between the two BRAF tumor subtypes is, however, not entirely clear.
Our computational analysis of multiple genomic data from TCGA suggested that V600K tumors had higher c-Kit protein and KIT gene expression levels than V600E tumors. We also found evidence of downregulation of proapoptotic proteins and upregulation of metabolism in V600K tumors compared with V600E tumors. Proteins involved in mRNA translation and ribosomal biogenesis were also upregulated in V600K tumors compared with V600E tumors, suggesting that the mTOR pathway [16] [17] [18] may be further activated in V600K tumors. Several proteins involved in DNA repair such as ATM, CHEK2, and PCNA also had higher expression in V600K tumors compared with V600E tumors ( Supplementary  Fig. S1A , Supplemental digital content 1, http://links.lww. com/MR/A6).
c-Kit is a receptor tyrosine kinase that plays a multifunctional role in melanogenesis, cell growth, migration, and survival [20, 21] . Activation of c-Kit either by the stem cell factor (a ligand) or oncogenic mutation activates the phosphatidylinositol 3-kiase signaling pathway as the dominant effector for cell proliferation and the mitogenactivated protein kinase cascade as an ancillary survival pathway [45, 46] . Although c-Kit plays an important role in normal melanocyte differentiation, growing evidence also suggests that it plays a role in melanoma progression [21] .
What caused the upregulation c-Kit and KIT expression in V600K tumors is unclear. We could find no association with somatic mutation, copy number alteration, or KIT promoter methylation data. KIT has been shown to be transcriptionally regulated by MITF [47, 48] . However, MITF gene expression did not differ between V600K and V600E tumors (data not shown).
We found that mir-222 expression was significantly downregulated in V600K tumors compared with V600E tumors. Mir-222 is known to regulate c-Kit protein and KIT gene expression. Thus, it is possible that upregulation of c-Kit resulted from downregulation of mir-222. The three genes (GNA11, KIT, and PTEN) with significant difference between the two subtypes are given in bold Data are taken from the supplementary table 1 of TCGA publication [2] . p Value was computed using a two-side Fisher's exact test.
If so, what caused the downregulation of mir-222 in V600K tumors? No differential methylation changes (TCGA methylation450 data, not shown) between V600K and V600E tumors were found in the promoter of the human mir-222 gene. Mir-222 expression has been shown to be regulated transcriptionally by several transcription factors. The promyelocytic leukemia zinc finger (PLZF) transcription factor represses mir-222 expression in cutaneous melanoma [22] . PLZF (ZBTB16) expression was not differential between V600K and V600E subtypes, however (data not shown). Other transcription factors known to regulate mir-222 expression include AML1 (RUXN1) [31] , AP-1 [40] , FOSL1 [42] , and NF-κB and c-Jun [49] . Although FOSL2 and RUNX3 were significantly downregulated in V600K tumors compared with V600E tumors, whether either of the two played a role in the differential regulation of mir-222 expression is unclear. Hypoxia has been shown to downregulate mir-222 expression [50] , raising the question of whether hypoxia in V600K tumors is more severe than in V600E tumors. Besides c-Kit, mir-222 is also known to target at least four tumor suppressors (PTEN, p27, p57, and TIMP3), suggesting that having the 'right' dosage of mir-222 may be critical, if its expression level was manipulated for potential therapeutic benefit.
We suggest that upregulation of c-Kit protein and KIT gene expression, downregulation of mir-222, and increased metabolic signals may be linked. We believe that enhanced growth and prosurvival signals in V600K tumors compared with V600E tumors may in be part responsible for the observed clinical aggressiveness of V600K tumors.
Finally, our observations/conclusions were based on a small number of V600K tumors (13) (14) (15) (16) (17) (18) (19) versus a more substantial number of V600E tumors (91-124). The sample sizes for some of the differentially expressed proteins identified in V600K tumors were smaller (4-13). The small sample size in V600K tumors is a major limitation of our study. If we had a larger sample of that subtype, our results could be different. It is important that our results are further validated in an independent study. Furthermore, underlying differences between V600E and V600K tumors are likely complex; c-Kit/mir-222 are likely not the only players. Mutation and copy number alteration data are from Cancer Genome Atlas Network [2] . The three tumors with the highest c-Kit expression are given in bold. NA, no data from TCGA. *Arginine 311 to a stop codon.
